Emerging Dealmaking Trends in Gene Therapy

In recent years, gene therapy products and technologies have been one of the most prominent drivers in dealmaking within the life sciences sector, despite the multiple challenges faced in drug development and commercialization. The number of gene therapy deals signed is now at its highest level in 5 years, with 310 deals signed in 2021 compared to only 164 in 2017. With recent clinical and regulatory advances, deal activity is likely to remain strong as companies race to secure a position in this lucrative market.

Business Intelligence

Go beyond the numbers to analytics-driven insights using artificial intelligence, machine learning and healthcare expertise.

Brand Strategy and Management

Be proactive about growing your brand using the latest in data, analytics, and domain expertise.

Commercialization

Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.

To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

Related solutions